Moderna advances investigational Bundibugyo ebolavirus vaccine toward Phase 2/3 study
MRNA•Moderna said it is advancing its investigational Bundibugyo ebolavirus vaccine toward a Phase 2/3 study through its expanded strategic collaboration with the Coalition for Epidemic Preparedness Innovations.
1. Vaccine development
Moderna said it is advancing its investigational Bundibugyo ebolavirus vaccine, mRNA-1469, toward a Phase 2/3 study through its expanded strategic collaboration with the Coalition for Epidemic Preparedness Innovations.
